Study of decision making about prostate cancer risk
Part of Cancer clinical trials.
This study looks at how men with a BRCA1/2 gene change make decisions about their health and prostate cancer risk. Participants will fill out surveys to help researchers understand these choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 45 and 70 years old.
- You must have been assigned male at birth.
- You must not have prostate cancer.
- You must have a confirmed BRCA1 or BRCA2 gene change found through genetic testing.
- You must be comfortable reading and completing surveys in English.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study asks women to complete surveys after learning their genetic risk results for certain breast cancer–related gene changes. It helps researchers understand how people respond and what they think or feel after getting these results.
This study looks at the genetics of breast cancer by collecting DNA from a saliva sample and asking you to fill out a health survey online. It's open to anyone in the U.S. who is 18 or older and can complete the study materials in English.
This study follows people who carry a harmful BRCA1 or BRCA2 gene mutation, whether or not they currently have breast or ovarian cancer. The goal is to better understand cancer risk over time and how being a carrier may affect screening and care.
This study looks at your personal and family risk for prostate cancer and helps decide who should have extra screening like MRI. It may help you find cancer earlier if you are at higher genetic risk.
This trial looks at how inherited risk (family history or gene findings) relates to screening and treatment for prostate cancer. If you qualify, you may be offered prostate screening tests and follow-up to see how well risk information predicts next steps.
This study looks at how Veterans with advanced prostate cancer make decisions about gene testing and possible targeted treatments, and how patients and caregivers understand the information. It may help by improving decision support for people facing germline and tumor testing choices.
Hear when a new BRCA1/2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.